ACE2 and COVID-19: Interestingly, gastrointestinal disorders have not been considered as comorbidities in COVID-19 despite observations of gut microbiota dysbiosis and decreased ACE-2 activity in the ileum of patients with Crohn's disease (Novak et al., 2020) and down-regulation of intestinal epithelial ACE-2 in IBD patients (Burgeno et al., 2020).